GlaxoSmithKline $GSK filed a Biologics License Application (BLA) with the FDA, seeking approval of its shingles vaccine, branded as Shingrix, for the prevention of herpes zoster in people aged 50 and above. In the clinical trials, a two-dose regimen of shingrix demonstrated 90% efficacy in participants at least 70 years old and was maintained in those aged 80 and over, considerably better than Merck�s $MRK ZOSTAVAX, which is merely 18% effective in people above 80 years. Regulatory submissions in Europe and Canada will be made before the end of the year, followed by Japan next year.